2017 Q1/Global Life Sciences
Rank | Chg | Organisation name | Overall |
|
---|---|---|---|---|
|
||||
1 | +45 |
Servier UK
|
8.5 | |
|
||||
2 | +16 |
HG Capital Trust
|
8.2 | |
|
||||
3 | +5 |
Julphar
|
7.6 | |
|
||||
4 | +21 |
QLT
|
7.5 | |
|
||||
5 | +19 |
Lexicon Pharmaceuticals
|
7.2 | |
|
||||
6 | +34 |
Bial Portela
|
7.1 | |
|
||||
7 | -5 |
Galenica AG
|
7.0 | |
|
||||
8 | +1 |
Meda Pharmaceuticals
|
7.0 | |
|
||||
9 | -4 |
Kyorin Holdings
|
6.9 | |
|
||||
10 | -3 |
Nissan Chemical
|
6.8 | |
|
||||
11 | -10 |
Taisho Pharmaceutical
|
6.7 | |
|
||||
12 | -1 |
Actelion
|
6.7 | |
|
||||
13 | +0 |
Debiopharm
|
6.7 | |
|
||||
14 | +50 |
Lilly
|
6.7 | |
|
||||
15 | +11 |
MannKind Corporation
|
6.3 | |
|
||||
16 | -2 |
Anika Therapeutics
|
6.3 | |
|
||||
17 | -14 |
Abbott Uk
|
6.3 | |
|
||||
18 | -12 |
MediGene
|
6.3 | |
|
||||
19 | +14 |
ARIAD Pharmaceuticals
|
6.3 | |
|
||||
20 | -16 |
Wockhardt
|
6.2 | |
|
||||
21 | -11 |
Biotecnol
|
6.2 | |
|
||||
22 | +130 |
Regeneron
|
6.0 | |
|
||||
23 | +36 |
Lundbeck
|
5.9 | |
|
||||
24 | -5 |
Baxter International
|
5.9 | |
|
||||
25 | -13 |
Mitsubishi Tanabe Pharma Europe Ltd
|
5.9 | |
|
||||
26 | -10 |
Yakult UK
|
5.8 | |
|
||||
27 | -10 |
Mitsubishi Tanabe
|
5.8 | |
|
||||
28 | -13 |
Abbott
|
5.8 | |
|
||||
29 | -8 |
Bavarian Nordic
|
5.8 | |
|
||||
30 | +15 |
Asahi Kasei
|
5.7 | |
|
||||
31 | -3 |
Nippon Chemiphar
|
5.7 | |
|
||||
32 | -1 |
EISAI
|
5.6 | |
|
||||
33 | +8 |
Sanofi UK
|
5.6 | |
|
||||
34 | -12 |
Ipsen UK
|
5.6 | |
|
||||
35 | +16 |
Mochida
|
5.6 | |
|
||||
36 | +99 |
Akorn
|
5.5 | |
|
||||
37 | -3 |
Dainippon Sumitomo
|
5.5 | |
|
||||
38 | +23 |
Enzo Biochem
|
5.5 | |
|
||||
39 | -19 |
EISAI UK
|
5.3 | |
|
||||
40 | -5 |
Pfizer UK
|
5.3 | |
|
||||
41 | -14 |
Kaken Pharmaceutical
|
5.3 | |
|
||||
42 | -3 |
Genmab
|
5.2 | |
|
||||
43 | -11 |
Galderma
|
5.2 | |
|
||||
44 | -7 |
Takeda UK
|
5.2 | |
|
||||
45 | -2 |
Apotex
|
5.2 | |
|
||||
46 | +72 |
Sawai Pharmaceutical
|
5.2 | |
|
||||
47 | +0 |
Stallergenes UK
|
5.2 | |
|
||||
48 | +1 |
Vitrolife
|
5.1 | |
|
||||
49 | +7 |
Covence
|
5.1 | |
|
||||
50 | -14 |
Merz
|
5.1 | |
|
Changes in rank are compared to 2016 Q4/Global Life Sciences. Since then, 3 sites entered the survey and 54 sites could not be included in the rankings (same since last). Build your own. Report statistics.
Priorities Summary
The priorities for this organization are not currently available to view.
Contact Us